Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 4/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.48 |
| ▸ | GSR | P00390 | 2/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.48 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.48 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6267781 | 0.87 | SLC1A1 (0.54) | SLC1A1SLC1A3SLC1A2GRIK1GRIK2 | |
| SCHEMBL2994699 | 0.87 | SLC1A1 (0.54) | SLC1A1SLC1A3SLC1A2GRIK1GRIK2 | |
| SCHEMBL7717181 | 0.87 | SLC1A1 (0.54) | SLC1A1SLC1A3SLC1A2GRIK1GRIK2 | |
| SCHEMBL931954 | 0.87 | SLC1A1 (0.54) | SLC1A1SLC1A3SLC1A2GRIK1GRIK2 | |
| SCHEMBL3918242 | 0.87 | SLC1A1 (0.54) | SLC1A1SLC1A3SLC1A2GRIK1GRIK2 | |
| SCHEMBL3430330 | 0.87 | SLC1A1 (0.54) | SLC1A1SLC1A3SLC1A2GRIK1GRIK2 | |
| SCHEMBL1273617 | 0.85 | SLC1A1 (0.50) | SLC1A1SLC1A3SLC1A2GRIK1GRIK2 | |
| SCHEMBL5604914 | 0.85 | SLC1A1 (0.52) | SLC1A1SLC1A3SLC1A2GRIK1GRIK2 | |
| SCHEMBL9857204 | 0.85 | SLC1A1 (0.52) | SLC1A1SLC1A3SLC1A2GRIK1GRIK2 | |
| SCHEMBL27976398 | 0.85 | SLC1A1 (0.52) | SLC1A1SLC1A3SLC1A2GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | UNIV CALIFORNIA (US) | 2026-03-19 | — | — | US | disclosed |
| US-20220102000-A1 | PREDICTING BLOOD METABOLITES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-03-31 | — | — | US | disclosed |
| EP-3918603-A1 | PREDICTING BLOOD METABOLITES | Yeda Research and Development Co. Ltd (IL) | 2021-12-08 | — | — | EP | disclosed |
| US-10634686-B2 | Biomarkers related to organ function | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-04-28 | — | — | US | disclosed |
| US-10175233-B2 | Biomarkers for cardiovascular diseases and methods using the same | METABOLON, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| WO-2017029498-A1 | 2-SULFONYLPYRIMIDINES | MEDICAL RESEARCH COUNCIL (GB) | 2017-02-23 | — | — | WO | disclosed |
| US-20160231330-A1 | BIOMARKERS RELATED TO ORGAN FUNCTION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160178620-A1 | Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and other Metabolic-Syndrome Related Disorders and Methods Using the Same | METABOLON, INC. | 2016-06-23 | — | — | US | disclosed |
| US-9250225-B2 | Biomarkers for insulin resistance and methods using the same | METABOLON, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| WO-2015042602-A1 | BIOMARKERS RELATED TO ORGAN FUNCTION | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-03-26 | — | — | WO | disclosed |
| US-7405227-B2 | Treatment of cancer | BIPAR SCIENCES, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080103104-A1 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| EP-1906948-A2 | TREATMENT OF CANCER | Bipar Sciences, Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007011962-A2 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015837-A1 | Treatment of Cancer | BIPAR SCIENCES, INC. | 2007-01-18 | — | — | US | disclosed |
| US-6127165-A | NUCLEIC ACID WHICH ENCODES ENZYME HAVING DEFINED AMINO ACID SEQUENCE; USED TO PREPARE GLUTATHIONE ANALOGS AND ANTIBODIES AGAINST ENZYME, DETECT GENE IN ANIMALS, MODIFY ENZYME PRODUCTION, CONSTRUCT MODELS FOR EVALUATION OF THERAPIES | CORNELL RESEARCH FOUNDATION, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| US-5747329-A | Glutamylcysteine synthetase light subunit | CORNELL RESEARCH FOUNDATION, INC. (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0693122-A4 | GLUTAMYLCYSTEINE SYNTHETASE LIGHT SUBUNIT | CORNELL RES FOUNDATION INC (US) | 1997-10-22 | — | — | EP | disclosed |
| EP-0693122-A1 | GLUTAMYLCYSTEINE SYNTHETASE LIGHT SUBUNIT | CORNELL RESEARCH FOUNDATION, INC. (US) | 1996-01-24 | — | — | EP | disclosed |
| WO-1994024276-A1 | GLUTAMYLCYSTEINE SYNTHETASE LIGHT SUBUNIT | CORNELL RESEARCH FOUNDATION, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015837-A1 | Treatment of Cancer | PARP1, PARP2, PARP3 | SLC1A1 4710/4885SLC1A3 4794/4885SLC1A2 4845/4885 |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | IDO1, INMT, IDO2 | SLC1A1 149/4885SLC1A3 141/4885SLC1A2 94/4885 |
| US-20080103104-A1 | TREATMENT OF CANCER | PARP1, PARP2, PARP3 | SLC1A1 4710/4885SLC1A3 4794/4885SLC1A2 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.